iRadimed (NASDAQ:IRMD) CEO Sells $427,950.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $85.59, for a total value of $427,950.00. Following the completion of the sale, the chief executive officer directly owned 2,312,500 shares of the company’s stock, valued at $197,926,875. The trade was a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

iRadimed Stock Performance

NASDAQ:IRMD traded up $0.10 on Wednesday, hitting $86.28. The stock had a trading volume of 39,247 shares, compared to its average volume of 49,167. The stock has a market cap of $1.10 billion, a P/E ratio of 53.18 and a beta of 1.04. The firm’s fifty day simple moving average is $76.26 and its two-hundred day simple moving average is $66.59. iRadimed Corporation has a 1 year low of $47.48 and a 1 year high of $87.88.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.04. The business had revenue of $21.20 million for the quarter, compared to analysts’ expectations of $20.50 million. iRadimed had a return on equity of 23.30% and a net margin of 26.61%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS. FY 2025 guidance at 1.840-1.880 EPS. Equities research analysts predict that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 25th. Investors of record on Friday, November 14th will be paid a $0.17 dividend. The ex-dividend date is Friday, November 14th. This represents a $0.68 annualized dividend and a yield of 0.8%. iRadimed’s dividend payout ratio is presently 41.21%.

Institutional Trading of iRadimed

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Roubaix Capital LLC bought a new position in iRadimed in the 1st quarter valued at approximately $2,526,000. SG Americas Securities LLC raised its holdings in iRadimed by 408.8% in the 2nd quarter. SG Americas Securities LLC now owns 36,516 shares of the medical equipment provider’s stock worth $2,183,000 after purchasing an additional 29,339 shares during the period. Nuveen LLC purchased a new position in shares of iRadimed during the 1st quarter valued at about $1,418,000. Johnson Investment Counsel Inc. bought a new position in shares of iRadimed in the second quarter worth approximately $1,534,000. Finally, Algert Global LLC boosted its holdings in iRadimed by 87.5% in the 3rd quarter. Algert Global LLC now owns 50,797 shares of the medical equipment provider’s stock worth $3,615,000 after buying an additional 23,710 shares during the period. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Analysts Set New Price Targets

IRMD has been the subject of several research reports. Zacks Research upgraded iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Lake Street Capital restated a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Roth Capital set a $90.00 price objective on iRadimed in a report on Friday, October 31st. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of iRadimed in a research report on Friday, October 31st. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.33.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.